IPSC insider transaction filings
Century Therapeutics, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-18. Screen IPSC transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-18 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 31,172 @ $1.92 | EDGAR |
| 2026-08-05 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 275 @ $1.98 | EDGAR |
| 2026-06-15 | 4 | Cowan Chad — Chief Scientific Officer | Tax withholding (F): 358 @ $2.24 | EDGAR |
| 2026-06-15 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 13,849 @ $2.24 | EDGAR |
| 2026-06-15 | 4 | Russotti Gregory — See Remarks | Sale (S): 2,584 @ $2.23 | EDGAR |
| 2026-06-15 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 1,654 @ $2.23 | EDGAR |
| 2026-06-12 | 4 | Murphy Martin Patrick — Director | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Lee Han Myung — Director | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Riva Alessandro — Director | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Blackwell Kimberly — Director | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4 | Quimi Daphne — Director | Grant/award (A): 74,000 (derivative) @ $0 | EDGAR |
| 2026-06-09 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 463 @ $2.13 | EDGAR |
| 2026-06-09 | 4 | Russotti Gregory — See Remarks | Sale (S): 524 @ $2.11 | EDGAR |
| 2026-06-09 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 249 @ $2.11 | EDGAR |
| 2026-05-19 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 31,172 @ $2.34 | EDGAR |
| 2026-05-06 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 264 @ $2.34 | EDGAR |
| 2026-04-10 | 4 | Murphy Martin Patrick — Director | Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Cowan Chad — Chief Scientific Officer | Tax withholding (F): 1,365 @ $2.19 | EDGAR |
| 2026-03-16 | 4 | Russotti Gregory — See Remarks | Sale (S): 10,076 @ $2.55 | EDGAR |
| 2026-03-16 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 7,043 @ $2.55 | EDGAR |
| 2026-03-13 | 4 | Cowan Chad — Chief Scientific Officer | Tax withholding (F): 1,431 @ $2.73 | EDGAR |
| 2026-03-13 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 55,397 @ $2.73 | EDGAR |
| 2026-03-11 | 4 | Russotti Gregory — See Remarks | Sale (S): 479 @ $2.54 | EDGAR |
| 2026-03-11 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 247 @ $2.54 | EDGAR |
| 2026-03-10 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 463 @ $2.56 | EDGAR |
| 2026-02-18 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 31,172 @ $1.75 | EDGAR |
| 2026-02-05 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 323 @ $1.82 | EDGAR |
| 2026-02-04 | 4 | Cowan Chad — Chief Scientific Officer | Grant/award (A): 135,000 @ $0 · Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Pfeiffenberger Brent — President and CEO, Director | Grant/award (A): 475,000 @ $0 · Grant/award (A): 945,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Russotti Gregory — See Remarks | Grant/award (A): 135,000 @ $0 · Grant/award (A): 265,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Carr Douglas — SVP Finance & Operations | Grant/award (A): 110,000 @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Cowan Chad — Chief Scientific Officer | Tax withholding (F): 1,611 @ $0.99 | EDGAR |
| 2025-12-29 | 4 | Cowan Chad — Chief Scientific Officer | Purchase (P): 58,060 @ $0.85 | EDGAR |
| 2025-12-16 | 4 | Pfeiffenberger Brent — President and CEO, Director | Purchase (P): 52,000 @ $0.58 | EDGAR |
| 2025-12-12 | 4 | Pfeiffenberger Brent — President and CEO, Director | Tax withholding (F): 463 @ $0.53 | EDGAR |
| 2025-12-11 | 4 | Lee Han Myung — Director | Grant/award (A): 88,000 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | Russotti Gregory — See Remarks | Sale (S): 526 @ $0.53 | EDGAR |
| 2025-12-10 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 257 @ $0.53 | EDGAR |
| 2025-11-24 | 4 | Cowan Chad — Chief Scientific Officer | Sale (S): 5,462 @ $0.50 | EDGAR |
| 2025-11-20 | 4 | Pfeiffenberger Brent — President and CEO, Director | Purchase (P): 35,000 @ $0.50 | EDGAR |
| 2025-11-19 | 4 | Pfeiffenberger Brent — President and CEO, Director | Sale (S): 32,456 @ $0.45 | EDGAR |
| 2025-11-05 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 292 @ $0.59 | EDGAR |
| 2025-09-22 | 4 | Cowan Chad — Chief Scientific Officer | Grant/award (A): 762,543 @ $0 | EDGAR |
| 2025-09-10 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 263 @ $0.50 | EDGAR |
| 2025-09-10 | 4 | Pfeiffenberger Brent — President and CEO, Director | Sale (S): 488 @ $0.50 | EDGAR |
| 2025-09-10 | 4 | Russotti Gregory — See Remarks | Sale (S): 539 @ $0.50 | EDGAR |
| 2025-08-18 | 4 | Pfeiffenberger Brent — President and CEO, Director | Grant/award (A): 1,587,614 @ $0 | EDGAR |
| 2025-08-06 | 4 | Carr Douglas — SVP Finance & Operations | Sale (S): 296 @ $0.53 | EDGAR |
| 2025-06-16 | 4 | Riva Alessandro — Director | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Carlo Rizzuto — Director | Grant/award (A): 44,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Century Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-06-12 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-23 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IPSC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →